世界中医药

目的：观察丹栀逍遥散加减对肝郁气滞型新生血管性青光眼的临床疗效及其与HIF-1/VEGF/Notch1信号通路相关性探讨。方法：将42例肝郁气滞型新生血管性青光眼患者随机分成2组，治疗组给予丹栀逍遥散加减+降眼压药物口服，对照组予降眼压药物，观察2组治疗4周后眼压、视力、视野、新生血管回退情况等；应用Western Blot检测2组患者血清中HIF-1a、VEGF、Notch1蛋白表达情况。结果：2组经不同方法治疗4周后眼压、视力、视野、新生血管情况比较有统计学意义（P<0.05），治疗组经丹栀逍遥散加减口服治疗与对照组比较，HIF-1a、VEGF、Notch1的蛋白表达情况明显低于对照组，且有统计学意义（P<0.05）。结论：丹栀逍遥散加减治疗新生血管性青光眼可以有效控制眼压，提高视力、视野，促使新生血管消退，是一种安全有效的治疗方式，值得临床推广应用，其作用机制可能是通过调控HIF-1/VEGF/Notch信号通路来实现的。

English Summary:

To observe clinical curative effect of Danzhi Xiaoyao Powder in the therapy of ganyu qizhi type of neovascularglaucoma（NVG） and deeply investigate the relationship between this effect and HIF-1/VEGF/Notch1 pathway. Methods: A total of 42 patients NVG were randomly divided into into 2 groups，21 patients in treatment group were treated with modified Danzhi Xiaoyao Powder and iop drugs，21 patients in control group were treated with only iop drugs.Observe the two groups after treatment of 4 weeks, intraocular pressure, visual ，view and new blood vessels.The expression of HIF-1a、VEGF、Notch1 at the protein level was assessed by Western Blot．Results: Significant differences were observed in terms of intraocular pressure, visual, view and new blood vessels (P<0.05). Compared with the control group, the expression of HIF-1a, VEGF, Notch1 level in the treatment group were significantly decreased (P<0.05). Conclusion: Danzhi Xiaoyao Powder in the treatment of NVG may effectively control the intraocular pressure, improve eyesight and restrain new blood vessels. It is a safe and effective treatment, worthy of clinical popularization and application. Its mechanism may be related to the regulation of HIF-1/VEGF/Notch1 signaling pathway.

查看全文查看/发表评论下载PDF阅读器